Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Adma Biologics (ADMA) closed at $19.50, indicating a -1.37% shift from the previous trading day.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
ADMA Biologics: Riding High On ASCENIV's Success
ADMA Biologics reported $107.2 million in Q2 2024 revenue, a 78% year-over-year increase, with ASCENIV being the primary growth driver. ASCENIV now contributes over 50% of ADMA's total revenue, with significant market potential in treating refractory immunodeficient patients. ASCENIV's unique formulation and potential market penetration could drive peak annual sales over $1 billion, though technological advancements and existing competition pose risks.
Adma Biologics (ADMA) Is a Great Choice for 'Trend' Investors, Here's Why
Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Biotech Hangs On To Top Spot On This List, And It Even Outshines Nvidia
This biopharma stock has gained around 330% so far this year and is near record highs.
Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $19.44, denoting a -0.26% change from the preceding trading day.
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?
ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
Here's Why Momentum in Adma Biologics (ADMA) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Adma Biologics (ADMA) Recently Broke Out Above the 20-Day Moving Average
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
ADMA Biologics Inc (ADMA) Hit a 52 Week High, Can the Run Continue?
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
